CYP2C8 and COVID-19: COVID-19 patients in Africa could experience adverse drug response when treated with chloroquine and hydroxychloroquine, since variants G6PD rs2230037 and CYP2C8 rs11572103 have considerable high AAF (26.7% and 18.9%, respectively).